Table 2.
Clinical data on people used for osteoclast culture
| Number | Sex | Age | Duration (years) | CRP (mg/L) |
ESR (mm/h) |
DAS28-ESR | Anti-CCP (U/mL) | RF (IU/mL) |
csDMARDs | bDMARDs/ tsDMARDs |
Glucocorticoid | Bone erosion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RA1 | F | 58 | 18 | 5 | 57 | 6.44 | 116 | < 20 | MTX + LEF | No | No | No |
| RA2 | F | 68 | 18 | 13.5 | 58 | 6.19 | 179 | < 20 | IGU + HCQ+SSZ | No | No | No |
| RA3 | F | 67 | 10 | 0.62 | 13 | 2.79 | < 8 | < 20 | No | No | No | Yes |
| RA4 | F | 75 | 6 | 1.81 | 45 | 6.00 | 124 | 1980 | MTX + HCQ+IGU | ADA | Yes | Yes |
| RA5 | F | 71 | 8 | 0.25 | 12 | 2.04 | < 8 | < 20 | LEF + HCQ+SSZ + IGU | No | Yes | - |
| RA6 | F | 70 | 36 | 0.65 | 55 | 3.88 | 65.5 | 30.2 | TG | No | Yes | No |
| RA7 | F | 43 | 18 | 0.35 | 16 | 4.50 | 8885 | 213 | No | No | No | Yes |
| RA8 | F | 59 | 3 | 22.4 | 30 | 4.68 | 197 | 63.7 | No | No | No | No |
| N1 | F | 25 | - | - | - | - | - | - | - | - | - | - |
| N2 | M | 40 | - | - | - | - | - | - | - | - | - | - |
| N3 | F | 47 | - | - | - | - | - | - | - | - | - | - |
| N4 | F | 38 | - | - | - | - | - | - | - | - | - | - |
RA: rheumatoid arthritis
CRP: C-reactive protein
ESR: erythrocyte sedimentation rate
DAS28-ESR: disease activity score in 28 joints base on ESR
Anti-CCP: anti-cyclic citrullinated peptide antibody
RF: rheumatoid factor
csDMARDs: conventional synthetic disease-modifying antirheumatic drugs
b/tsDMARDs: biological/targeted synthetic DMARDs
MTX: methotrexate
LEF: leflunomide
IGU: iguratimod
HCQ: hydroxychloroquine
SSZ: sulfasalazine
TG: thunder god vine, phytotherapeutic agents for rheumatism
ADA: adalimumab